VEGF

XyloCor Therapeutics Presents Phase 2 Data Highlighting Safety and Efficacy of XC001 at the European Society of Cardiology (ESC) Congress 2023

Retrieved on: 
пятница, августа 25, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Heart, Pericardium, Duke University School of Medicine, Prevalence, ESC Congress, Angina, Cardiovascular disease, Quality of life, European Society of Cardiology, PET, Blood, Congress, VEGF, Ischemia, Patient, ST depression, European Society of Gene and Cell Therapy, ESC, Joe Byrd (Cherokee Nation Principal Chief), Therapy, Positron emission tomography, Safety, Pharmaceutical industry

The findings underscore its strong potential as a novel therapeutic approach for the treatment of this disabling condition.

Key Points: 
  • The findings underscore its strong potential as a novel therapeutic approach for the treatment of this disabling condition.
  • XC001 met all of its safety and exploratory objectives and showed potential transformative benefits for the patient population.
  • Among the notable topline results presented at the ESC Congress 2023 included:
    VEGF gene therapy with XC001 administered via minimally invasive transepicardial delivery was generally well tolerated.
  • “We are excited to share data that provides evidence for angiogenesis and a promising efficacy and tolerability profile for XC001.

Glioma in the 7MM: Insights, Epidemiology and Forecast to 2032 - Promising Advances in Treatment and Challenges in Access and Reimbursement - ResearchAndMarkets.com

Retrieved on: 
четверг, августа 24, 2023
Biotechnology, General Health, Health, Pharmaceutical, Oncology, EU4, DNA, Bevacizumab, Malignancy, Radiation, Temozolomide, GBM, Survivin, Neoplasm, Epidemiology, Survival, Forest Law Enforcement and Governance Program, Cancer, Genentech, Immunotherapy, USD, Incidence, VEGF, Health insurance coverage in the United States, Congress of Neurological Surgeons, VBL, AANS, American Association of Neurological Surgeons, Patient, Patent, Ofranergene obadenovec, IDH1, Growth, Merck, FDA, Therapy, Disease, Mobile phone, Health care, Pharmaceutical industry, Glioma

The report offers insights into glioma's epidemiology, current treatments, emerging therapies, market dynamics, and challenges related to treatment access and reimbursement.

Key Points: 
  • The report offers insights into glioma's epidemiology, current treatments, emerging therapies, market dynamics, and challenges related to treatment access and reimbursement.
  • Epidemiology: Glioma's epidemiology is discussed for the 7MM (United States, EU4 countries, UK, and Japan) from 2019 to 2032.
  • The United States contributed the highest incident cases, with Grade IV glioma being the most prevalent.
  • Market Access and Reimbursement: Reimbursement for rare disease therapies faces challenges due to high costs and lack of policies.

MEI Pharma Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN®) in Patients with Previously Treated Metastatic Colorectal Cancer

Retrieved on: 
среда, августа 16, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Bevacizumab, Cancer, OXPHOS, Woman, Trial of the century, VEGF, Rutgers Cancer Institute of New Jersey, Cooper University Hospital, Patient, Colorectal cancer, Pharmaceutical industry

MEI Pharma, Inc. (NASDAQ: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the dosing of the first patient in a Phase 1b study evaluating ME-344 in combination with bevacizumab (AVASTIN®) in patients with previously treated metastatic colorectal cancer.

Key Points: 
  • MEI Pharma, Inc. (NASDAQ: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the dosing of the first patient in a Phase 1b study evaluating ME-344 in combination with bevacizumab (AVASTIN®) in patients with previously treated metastatic colorectal cancer.
  • ME-344 is a novel mitochondrial inhibitor targeting energy production through the OXPHOS pathway, which is important for supporting tumor cell survival and proliferation for many forms of cancer, including colorectal cancer.
  • “This clinical study presents an important opportunity to evaluate a novel approach to treatment with the potential to bring improved benefit to patients.
  • This target is quite unlike other treatments for colorectal cancer, and will be studied by investigators at the Rutgers Cancer Institute Metabolomics Center of Excellence in conjunction with the trial.

The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed

Retrieved on: 
среда, июля 26, 2023
Bevacizumab, IgG4-related ophthalmic disease, Clinical trial, Research, IVT, VEGF, Eye, Patient, European, Visual acuity, Death, KDR, Endothelium, Safety, Pharmaceutical industry, Vaccine, EU

This single-arm, open-label, multicentre, phase I/II study aimed to evaluate the safety and preliminary efficacy of EB12-20145P (HLX04-O) via intravitreal injection (IVT) in patients with active wet age-related macular degeneration (wAMD).

Key Points: 
  • This single-arm, open-label, multicentre, phase I/II study aimed to evaluate the safety and preliminary efficacy of EB12-20145P (HLX04-O) via intravitreal injection (IVT) in patients with active wet age-related macular degeneration (wAMD).
  • Part 2 was a single-arm, open-label, multicentre, phase II study and 20 patients (including 6 patients from part 1) were enrolled in this part.
  • As of now, the clinical trial applications of EB12-20145P (HLX04-O) had been approved in Singapore and other countries and regions.
  • EB12-20145P (HLX04-O) has the potential to be one of the first bevacizumab approved for use in ophthalmic diseases, benefiting more patients with eye diseases worldwide.

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2023

Retrieved on: 
среда, августа 9, 2023
Biotechnology, Health, Science, Pharmaceutical, Research, Monoclonal antibody, US Food Sovereignty Alliance, Clinical trial, OS, Trae tha Truth, Quality of life, TKI, NSCLC, Immunotherapy, Lung cancer, PFS, ASCO, VEGF, Hair, American Society of Clinical Oncology, Patient, Investment, EGFR, Anemia, Annual general meeting, SMMT, Webcast, Knowledge, PD-1, FDA, Phase, Collaboration, Society, ORR, Pharmaceutical industry, Road, Security (finance), Cryptocurrency, Rare-earth element

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the second quarter and six months ended June 30, 2023.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the second quarter and six months ended June 30, 2023.
  • Summit intends to dose patients in the HARMONi-3 trial during the second half of 2023.
  • Net loss for the three and six months ended June 30, 2023 was $14.7 million and $557.1 million, respectively.
  • Operating cash outflow for the six months ended June 30, 2023 and 2022 was $42.4 million and $38.2 million, respectively.

4DMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ASRS 2023

Retrieved on: 
суббота, июля 29, 2023
PRISM, Anti-VEGF, Retinal, DME, Clinical trial, AMD, Geographic atrophy, ASRS, Intraocular pressure, Diabetic retinopathy, Cavg, VEGF, SAE, Science, Patient, Intravitreal administration, CST, Annual general meeting, Assessment, FDA, Society, Pharmaceutical industry, Birth control, Vaccine, Veterinary medicine, Electrophysiology

4D-150 is a potentially transformative genetic medicine that utilizes 4DMT’s evolved and customized retinotropic R100 vector, while targeting four VEGF family members.

Key Points: 
  • 4D-150 is a potentially transformative genetic medicine that utilizes 4DMT’s evolved and customized retinotropic R100 vector, while targeting four VEGF family members.
  • 4D-150 is being developed as a single dose, routine outpatient intravitreal therapy with the goal of reducing treatment burden and maintaining efficacy in patients with wet AMD and diabetic macular edema (DME).
  • “We look forward to continuing to build upon 4D-150’s strong profile to date in the randomized Phase 2 stage of the PRISM trial in patients with wet AMD and the Phase 2 SPECTRA trial in patients with DME.
  • cMean ±SE of -0.5 ±2.1 when including all patients (n=10).

4DMT Completes Enrollment of Phase 2 PRISM Clinical Trial for Intravitreal 4D-150 in Patients with Wet AMD and Reports Interim Safety and Tolerability Data

Retrieved on: 
понедельник, июля 17, 2023
PRISM, DME, AMD, Clinical trial, Inflammation, VEGF, Patient, Physician, FDA, Safety, Pharmaceutical industry

The targeted enrollment of the trial was 50 wet AMD patients randomized 2:2:1 to 3E10 vg/eye or 1E10 vg/eye of 4D-150 or aflibercept.

Key Points: 
  • The targeted enrollment of the trial was 50 wet AMD patients randomized 2:2:1 to 3E10 vg/eye or 1E10 vg/eye of 4D-150 or aflibercept.
  • Initial interim Phase 2 clinical activity data, and further safety data updates, are expected to be reported in H1 2024.
  • “We are excited by the rapid pace and completion of enrollment of our Phase 2 PRISM trial driven by strong patient and physician interest,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.
  • Preliminary data from 4DMT’s clinical trials that it announces or publishes may change as more patient data becomes available and are subject to audit and verification procedures that could result in material changes in the final data.

REGENXBIO Highlights AAV Pipeline with Interim Results from Retinal and Duchenne Programs at its Virtual Investor Day on July 11, 2023

Retrieved on: 
вторник, июля 11, 2023
Interim, Myopathy, AMD, Cohort, ABBV, Eye, Quality of life, American Academy, DRSS, NAV, American Academy of Ophthalmology, RNA, Inflammation, AAV, Facial muscles, Duchenne muscular dystrophy, VEGF, Investigational New Drug, DMD, CGMP, Patient, AbbVie, Webcast, Diabetic retinopathy, Ageing, Phase, FDA, IND, Safety, Dietary supplement, Pharmaceutical industry, Cryptocurrency, Medical device, Vaccine, Duchenne, Ophthalmology

ROCKVILLE, Md., July 11, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) will announce today new interim data from the Phase II AAVIATE® and ALTITUDE® trials of ABBV-RGX-314 suprachoroidal delivery in wet AMD and diabetic retinopathy (DR). The company will also provide a comprehensive Duchenne program overview including initial safety data for RGX-202 and a new exon 53 program.

Key Points: 
  • REGENXBIO will host a virtual Investor Day today at 8:30 a.m.
  • The webcast and slides of the presentation can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com .
  • "Today, we are pleased to share an update on REGENXBIO's pipeline of AAV-based gene therapies with a focus on our retinal and Duchenne programs.
  • The virtual event will take place on Tuesday, July 11, 2023, at 8:30 a.m. Eastern Time.

Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Retrieved on: 
понедельник, июля 3, 2023
CD19, Takeda, Osteoporosis, CD20, Neoplasm, Biogen, VEGF, Patient, Epitope, Epithelial cell adhesion molecule, Zymeworks, Therapy, Lonza, Bone marrow, Research, Genentech, Gilead, EMA, Boehringer Ingelheim, ABL, Growth, ADC, PD-1, FDA, III, NMPA, Hubert Mordek, Roche, Docetaxel, Bispecific monoclonal antibody, Gilead Sciences, CD3, IGM, HER2, Immunoglobulin M, Conjugation, Cancer, Macrogen, Dragonfly, NSCLC, Antibody, Immunotherapy, Acute myeloid leukemia, CD33, Syndrome, Immune system, Pembrolizumab, Economics, Caris, Jazz, PRV, CEA, Diffuse large B-cell lymphoma, NHL, LAS, MDS, AML, CD123, Jazz Pharmaceuticals, Regeneron Pharmaceuticals, BCMA, Vaccine, Fine chemical, Pharmaceutical industry, WNT

LAS VEGAS, July 3, 2023 /PRNewswire/ -- DelveInsight's 'Bispecific Antibody Competitive Landscape – 2023' report provides comprehensive global coverage of available, marketed, and pipeline bispecific antibodies in various stages of clinical development, major pharmaceutical companies working to advance the pipeline space, company assessment, comparative assessment, and future growth potential of the bispecific antibody competitive domain.

Key Points: 
  • The bispecific antibody pipeline and clinical trial analysis report deliver important insights on ongoing research, clinical strategies, upcoming therapeutics, and commercial analysis.
  • Over 250+ bispecific antibody companies are evaluating 300+ bispecific antibody drugs in various stages of development, and their anticipated acceptance in the bispecific antibody market would significantly increase market revenue.
  • Promising bispecific antibody pipeline drugs such as Amivantamab, Blinatumomab, Ivonescimab, Zanidatamab, Glofitamab, Imvotamab, MGD024, PRV 3279, KN-046, SI-B001, REGN-5458, BI-905711, and others are under different phases of bispecific antibody clinical trials.
  • The collaboration is intended to help in the development and manufacturing of ABL Bio's new bispecific antibody product.

Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Retrieved on: 
понедельник, июля 3, 2023
CD19, Takeda, Osteoporosis, CD20, Neoplasm, Biogen, VEGF, Patient, Epitope, Epithelial cell adhesion molecule, Zymeworks, Therapy, Lonza, Bone marrow, Research, Genentech, Gilead, EMA, Boehringer Ingelheim, ABL, Growth, ADC, PD-1, FDA, III, NMPA, Hubert Mordek, Roche, Docetaxel, Bispecific monoclonal antibody, Gilead Sciences, CD3, IGM, HER2, Immunoglobulin M, Conjugation, Cancer, Macrogen, Dragonfly, NSCLC, Antibody, Immunotherapy, Acute myeloid leukemia, CD33, Syndrome, Immune system, Pembrolizumab, Economics, Caris, Jazz, PRV, CEA, Diffuse large B-cell lymphoma, NHL, LAS, MDS, AML, CD123, Jazz Pharmaceuticals, Regeneron Pharmaceuticals, BCMA, Vaccine, Fine chemical, Pharmaceutical industry, WNT

LAS VEGAS, July 3, 2023 /PRNewswire/ -- DelveInsight's 'Bispecific Antibody Competitive Landscape – 2023' report provides comprehensive global coverage of available, marketed, and pipeline bispecific antibodies in various stages of clinical development, major pharmaceutical companies working to advance the pipeline space, company assessment, comparative assessment, and future growth potential of the bispecific antibody competitive domain.

Key Points: 
  • The bispecific antibody pipeline and clinical trial analysis report deliver important insights on ongoing research, clinical strategies, upcoming therapeutics, and commercial analysis.
  • Over 250+ bispecific antibody companies are evaluating 300+ bispecific antibody drugs in various stages of development, and their anticipated acceptance in the bispecific antibody market would significantly increase market revenue.
  • Promising bispecific antibody pipeline drugs such as Amivantamab, Blinatumomab, Ivonescimab, Zanidatamab, Glofitamab, Imvotamab, MGD024, PRV 3279, KN-046, SI-B001, REGN-5458, BI-905711, and others are under different phases of bispecific antibody clinical trials.
  • The collaboration is intended to help in the development and manufacturing of ABL Bio's new bispecific antibody product.